News: CMN Weekly (17 December 2021) - Your Weekly...
Dec. 17, 2021
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
AstraZeneca
Main focus: Many different therapeutic areas including oncology, cardiovascular, neurological diseases and others
Company stage: Commercial
Diseases: Undisclosed
Genome editing technology: CRISPR-Cas9
Funding stage: Public (NASDAQ:AZN)
Location: Cambridge, England
Website: https://www.astrazeneca.com/
Pipeline: https://www.astrazeneca.com/our-therapy-areas/pipeline.html
AstraZeneca is a public, clinical-stage big pharma company focused on a wide array of therapeutic areas. AstraZeneca has worked with CRISPR-based therapeutic models on several occasions. The company demonstrated the use of CRISPR to reverse a mutation causing enzyme deficiency in an α1-antitrypsin-deficient mouse model. The company is also working closely with several global laboratories to develop new CRISPR tools such as CRISPR GUARD, CRISPR VIVO and DISCover-seq.
